Latest news with #Stockholm
Yahoo
2 hours ago
- Health
- Yahoo
Sobi will showcase extensive research and clinical outcomes at ISTH 2025
STOCKHOLM, June 20, 2025 /PRNewswire/ -- Sobi® (STO: SOBI) will be presenting a wide range of clinical study updates at the annual International Society on Thrombosis and Haemostasis (ISTH) Congress in Washington (21-25 June). With ten (10) presentations, Sobi's clinical teams will showcase new data for avatrombopag to treat children with ITP, surgery outcomes using efanesoctocog alfa, and abstracts on specific long-term haemophilia studies. "Attending ISTH is an important part of our commitment to collaboration and knowledge sharing so we can further advance treatments for those living with haemophilia, immune thrombocytopenia, and other rare blood conditions", said Lydia Abad-Franch, MD, Head of R&D and Medical Affairs, and Chief Medical Officer at Sobi. "We are proud to be showcasing abstracts as part of the ISTH programme, including Doptelet abstracts that present new data related to children living with ITP, Altuvoct outcomes for perioperative management, and joint health outcomes from a long-term extension study, as well as final outcomes from the B-MORE study. Many people living with rare conditions have unmet needs, and we are proud to present additional data advancing treatments for these rare conditions." Data to be presented at ISTH 2025 ALTUVOCT® (efanesoctocog alfa) OC 64.4: Major Surgical Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program Presenting author: Liane Khoo Oral presentation Session date: Tuesday 24 June Session time: 14:45 - 16:00 EDT Location: 151 A&B, Walter E. Washington CC Convention Center OC 20.5: Treatment of Bleeding Episodes with Efanesoctocog Alfa in Children: XTEND-ed Second Interim Analysis Presenting author: Lynn Malec Oral presentation Session date: Sunday 22 June Session time: 14:45 - 16:00 EDT Location: Ballroom A-C, Walter E. Washington CC Convention Center PB0847: Minor Surgeries Outcomes with Efanesoctocog Alfa: 4 Years' Experience in the XTEND Clinical Program Presenting author: Pratima Chowdary Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall PB1425: Joint Health Outcomes with Efanesoctocog Alfa in Adults/Adolescents from XTEND-1 Continuing XTEND-ed Presenting author: Christoph Königs Poster presentation Session date: Tuesday 24 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall General Haemophilia PB0778: Addressing unmet medical needs and health inequities in haemophilia A: expertconsensus statements Presenting author: Cédric Hermans Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall PB0816: Extravascular distribution of factor IX: evidence and relevance for haemophilia B replacement therapy Presenting author: Cédric Hermans Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall PB1439: Monitoring Joint Health in Haemophilia Patients in Spain: Updated Analysis of the JOIN-US Project Presenting author: María Teresa Álvarez Román Poster presentation Session date: Tuesday 24 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall ALPROLIX® (rFIXFc) PB0868: Real-World Effectiveness and Usage of Recombinant Factor IX Fc: Final Data from the B-MORE Study Presenting author: Heidi Glosli Poster presentation Session date: Monday 23 June Session time: 13:45 – 14:45 EDT Location: Exhibition Hall Doptelet® (avatrombopag) PB0348: Consistent Response to Avatrombopag for the Treatment of Children with ITP Across Various Baseline Characteristics Presenting author: Rachael F. Grace Poster presentation Session date: Sunday 22 June Session time: 13:45 - 14:45 EDT Location: Exhibition hall PB0364: Evaluation of Efficacy and Safety of Avatrombopag in Children with ITP Based on Disease Duration Presenting author: Rachael F. Grace Poster presentation Session date: Sunday 22 June Session time: 13:45 - 14:45 EDT Location: Exhibition hall OC 65.3: Real-World Outcomes of Avatrombopag Treatment in Primary ITP Stratified by Prior TPO-RA Exposure Presenting author: Srikanth Nagalla Oral presentation Session date: Tuesday 24 June 2025 Session time: 14:45 – 16:00 EDT (Presentation time currently in programme: 15:15 – 15:30 EDT) All abstracts are accessible through the official ISTH website. However, any late-breaking abstracts will only be made available later. About ALTUVOCT® (efanesoctocog alfa) ALTUVOCT® (efanesoctocog alfa) is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A. ALTUVOCT can be used for all age groups and any disease severity. About Elocta®/Eloctate® (efmoroctocog alfa) Elocta®/Eloctate® (efmoroctocog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia A. Elocta/Eloctate can be used for all age groups. About Alprolix® (eftrenonacog alfa) Alprolix® (eftrenonacog alfa) is a treatment and prophylaxis of bleeding in patients with haemophilia B. Alprolix can be used for all age groups. About Doptelet® (avatrombopag) Doptelet® (avatrombopag) is indicated for the treatment of primary chronic immune thrombocytopenia (ITP) in adult patients who are refractory to other treatments, and a treatment of severe thrombocytopenia in adult patients with chronic liver disease (CLD) who are scheduled to undergo an invasive procedure. About Sobi Sobi is a global biopharma company unlocking the potential of breakthrough innovations, transforming everyday life for people living with rare diseases. Sobi has approximately 1,900 employees across Europe, North America, the Middle East, Asia and Australia. In 2024, revenue amounted to SEK 26 billion. Sobi's share (STO:SOBI) is listed on Nasdaq Stockholm. More about Sobi at and LinkedIn. About Sanofi Sanofi is an R&D driven, AI-powered biopharma company committed to improving people's lives and delivering compelling growth. Sanofi apply deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Sanofi's team is guided by one purpose: to chase the miracles of science to improve people's lives; this inspires Sanofi to drive progress and deliver positive impact for Sanofi's people and the communities Sanofi serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY About the Sanofi and Sobi collaboration Sobi and Sanofi collaborate on the development and commercialisation of Alprolix and Elocta/Eloctate. The companies also collaborate on the development and commercialisation of efanesoctocog alfa, or ALTUVIIIO® in the US, Japan, and Taiwan, and Altuvoct in Europe. Sobi has final development and commercialisation rights in the Sobi territory (essentially Europe, North Africa, Russia, and most Middle Eastern markets). Sanofi has final development and commercialisation rights in North America and all other regions in the world excluding the Sobi territory. Contacts For details on how to contact the Sobi Investor Relations Team, please click here. For Sobi Media contacts, click here. This information was brought to you by Cision The following files are available for download: Sobi will showcase extensive research and clinical outcomes at ISTH 2025 View original content:
Vogue
5 hours ago
- Entertainment
- Vogue
Our Legacy Spring 2026 Menswear Collection
How to mark a milestone? At Our Legacy Cristopher Nying and team decided to take an introspective rather than retrospective approach to the season. The spring 2026 collection—called B-Sides—marks the Swedish brand's second decade. And it truly feels 20 years young, having retained a scruffy 'just kids' attitude while simultaneously becoming more refined. To build on the music metaphor introduced by the collection's title, OL bridges the analog/digital divide, retaining elements of the cassette tape and the audio file. It's refreshing, and completely in character, that Nying would shy away from a big anniversary blow-out in favor of pouring his energy and love into his passion: developing textiles and making clothes. The tactility of the pieces even seeps into the way they're described: Materials are washed, waxed, dipped, speckled, coarse, soft, worn, oily, glazed, and deep. Just as various are the collection's shades of black, including void, soot, whisker, deep abyss, jet, and more. There is also a wide range of khakis, as well as touches of bordeaux and purple. On a call, the designer described this season an 'internal process,' very much focused on in-jokes (see the Angry Fan Mail print made from actual correspondence received over the years). The starting point, as ever, is tailoring—sharp and technical or soft and deconstructed—along with biker and military influences. A couple of the looks reference the first vintage garment Nying bought: 'a pair of Swedish military overalls that we cut off and said 'This should be the Our Legacy jacket,' but we never really did it until now, which is very funny.' The men's and women's looks are more in harmony than they've ever been here. A man's uniform jacket is made feminine by shaping, while a small back slit, more commonly used in women's garb, is added to the men's version. Lace appears throughout the collection, including on military-inspired looks, and a large-scale camouflage intarsia reads more punk than hawkish. Also included are new, not nostalgic, takes on some OL hits, such as the tuxedo bomber or the 'angel of death' print introduced in the first collection in 2005. Enjoying their debuts are some materials that didn't make the edit the first time around, like an iridescent knit. 'It's something,' Nying said, 'that we've always talked about internally, how something is shifting.'
Vogue
5 hours ago
- Entertainment
- Vogue
Our Legacy Spring 2026 Ready-to-Wear Collection
How to mark a milestone? At Our Legacy, Cristopher Nying and team decided to take an introspective rather than retrospective approach to the season. The spring 2026 collection—called B-Sides—marks the Swedish brand's second decade. And it truly feels 20 years young, having retained a scruffy 'just kids' attitude while simultaneously becoming more refined. To build on the music metaphor introduced by the collection's title, OL bridges the analog-digital divide, retaining elements of the cassette tape and the audio file. It's refreshing, and completely in character, that Nying would shy away from a big anniversary blowout in favor of pouring his energy and love into his passion: developing textiles and making clothes. The tactility of the pieces even seeps into the way they're described: Materials are washed, waxed, dipped, speckled, coarse, soft, worn, oily, glazed, and deep. Just as various are the collection's shades of black, including void, soot, whisker, deep abyss, jet, and more. There is also a wide range of khakis, as well as touches of bordeaux and purple. On a call, the designer described this season an 'internal process,' very much focused on in-jokes (see the 'Angry Fan Mail' print made from actual correspondence received over the years). The starting point, as ever, is tailoring—sharp and technical, or soft and deconstructed—along with biker and military influences. A couple of the looks reference the first vintage garment Nying bought: 'a pair of Swedish military overalls that we cut off and said, 'This should be the Our Legacy jacket,' but we never really did it until now, which is very funny.' The men's and women's looks are more in harmony than they've ever been here. A man's uniform jacket is made feminine by shaping, while a small back slit, more commonly used in women's garb, is added to the men's version. Lace appears throughout the collection, including on military-inspired looks, and a large-scale camouflage intarsia reads more punk than hawkish. Also included are new, not nostalgic, takes on some OL hits, such as the tuxedo bomber or the 'Angel of Death' print introduced in the first collection in 2005. Enjoying their debuts are some materials that didn't make the edit the first time around, like an iridescent knit. 'It's something,' Nying said, 'that we've always talked about internally, how something is shifting.'
Free Malaysia Today
8 hours ago
- Business
- Free Malaysia Today
Sweden parliament backs US$31bil borrowing to boost defence
The parties in the Swedish parliament have been negotiating the defence deal in recent months. (EPA images pic) STOCKHOLM : Sweden's government said today that all parties in parliament have agreed to back its plan to invest heavily in the rearmament of the country's civil and military defence, and to pay for it with loans of up to SEK300 billion (US$31 billion). 'Sweden is in a very serious security situation,' defence minster Pal Jonson told a press conference. 'It is therefore very good that we can present a broad and long-term political agreement on very big defence investments in the coming years,' Jonson said. The parties have been negotiating the defence deal in recent months. 'Under the new defence agreement, Sweden plans to raise military defence spend to 3.5% of gross domestic product (GDP) by 2032 at the latest,' Jonson said.
Phone Arena
13 hours ago
- Phone Arena
Update to Google Maps in selected markets adds interesting AI feature
Google Maps has pushed out an update that is meant for users of the app in Europe. When you type in your destination, Google Maps typically searches for multiple routes for the navigation option you've selected (car, walking, public transportation, etc.). However, with the addition of AI, Google Maps will check the estimated time of arrival (ETA) of other modes to your destination. If you can reach your destination faster using public transportation or by walking, you'll see those directions on the display instead of directions for driving. If a different mode of transportation is faster than driving, Google Maps will show you directions using that mode. | Image credit-PhoneArena For example, let's say that you have Google Maps set up for driving directions and the app determines that you'll reach your destination faster by taking public transportation. Google Maps will then show you those suggested routes. Not only will you arrive earlier, by taking the bus you are reducing pollution, conserving gas, and doing your part to protect and preserve natural resources. This new feature is available in 60 European cities including Stockholm, Warsaw. and Copenhagen. In Europe, cycling is huge and Google Maps is adding cycling navigation to 17 new cities with nine of them located in Europe. The app now shows 125,000 kilometers (equal to 77,671 miles) of bike lanes in cities such as Hamburg, Madrid, Barcelona, Milan, Rome, Zurich, Budapest, Vienna, and Brussels. Google is using data obtained from local governments and public authorities. Since Google Maps is looking to get travelers to be more judicious in their consumption of natural resources, it now offers fuel-efficient routes worldwide. Previously, this feature was available only in certain regions. When you type a destination on the app, the fuel-efficient route is listed as an alternative. Each route also shows its ETA so that you'll know how much later you'll arrive at your destination by taking the more fuel-efficient option. Fuel-efficient directions show you how much gas you'll save when using this route. | Image credit-PhoneArena Google Maps is also adding support for low-emission zones which will impact drivers in Italy, Sweden, Austria, and other locations. Google Maps will send alerts that will "check if your vehicle is allowed in these zones." You can ask the app to create an alternate route that bypasses the low-emission zones. Google Maps will support over 1,000 low-emission zones. Google Maps now supports low-emission zones and will let you know if your car can drive into this zone. | Image credit-PhoneArena Project Green Light uses AI and Google Maps driving trends to help recommend to cities how they can improve their existing traffic light cycles. Project Green Light is available in 20 cities across four continents. Secure your connection now at a bargain price! We may earn a commission if you make a purchase This offer is not available in your area.
